Craig Wallace Seattle, WA (Vocus) May 9, 2010 Trupanion, a pet health insurance company based in Seattle, announces the recent hire of Craig Wallace as Senior Vice President of Marketing and Sales for the company. Craig comes to Trupanion with over 20 years of veterinary-related experience. Before joining the Trupanion team, [...]

Continue reading " Pet Insurance Company Hires Craig Wallace as Senior Vice President of Marketing and Sales "

Craig Wallace Seattle, WA (Vocus) May 9, 2010 Trupanion, a pet health insurance company based in Seattle, announces the recent hire of Craig Wallace as Senior Vice President of Marketing and Sales for the company. Craig comes to Trupanion with over 20 years of veterinary-related experience. Before joining the Trupanion team, [...]

Continue reading " Pet Insurance Company Hires Craig Wallace as Senior Vice President of Marketing and Sales "

China Pharmaceuticals, Inc. (OTCBB: CFMID) (“China Pharmaceuticals, Inc.” or the “Company”), one of China’s leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, announced record sales for its first quarter ended March 31, 2010. The Company’s quarterly report on Form 10-Q was filed on May 17, 2010 with the United States Securities and Exchange Commission. [...]

Continue reading " China Pharmaceuticals, Inc. Announces Record Sales for First Quarter 2010 "

Sanderson Farms, Inc. (NASDAQ: SAFM) reported results for its second fiscal quarter and six months ended April 30, 2010. Net sales for the second quarter of fiscal 2010 were $487.1 million compared with $426.8 million for the same period a year ago. For the quarter, net income was $35.1 million, or $1.62 per fully diluted [...]

Continue reading " Sanderson Farms, Inc. Reports Results for Second Quarter of Fiscal 2010 "

Herbalife Ltd. (NYSE:HLF) reported first quarter net sales increased 18.6 percent to $618.6 million and local currency net sales increased 13.3 percent compared to the same period in 2009. The record revenue reflects volume point growth of 6.2 percent and an increase in Average Active Sales Leaders of 7.4 percent, both compared to the first [...]

Continue reading " Herbalife Ltd. Announces Record First Quarter Revenue and Raises FY’10 EPS Guidance "

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced results for the first quarter ended March 31, 2010. * 2010 Total Net Revenue Guidance Reconfirmed at $627 – $652 Million * GAAP Basic and Diluted Net Income of $0.35 and $0.34 Per Share, Respectively, for 1Q10 * NON-GAAP Basic and Diluted Net Income of $0.61 and $0.53 Per [...]

Continue reading " Cubist Pharmaceuticals 1Q10 Total Net Revenues Up 19% to $144.1 Million "

Retractable Technologies, Inc. (“Retractable”) (NYSE AMEX: RVP), a leading maker of safety needle devices, announced an increase in revenues of 39.7% for the year 2009 over 2008. Revenues increased due principally to sales under the Department of Health and Human Services (“DHHS”) contract which was announced in the third quarter of 2009. The DHHS program, [...]

Continue reading " Retractable Technologies, Inc. (“Retractable”) (NYSE AMEX: RVP), a leading maker of safety needle devices, announced an increase in revenues of 39.7% for the year 2009 over 2008. Revenues increased due principally to sales under the Department of Health and Human Services (“DHHS”) contract which was announced in the third quarter of 2009. The DHHS program, which was estimated to run from August 2009 through March 2010, ended in December 2009. Our revenue increased 142.1% in the fourth quarter principally due to the DHHS contract. We do not know if there will be a similar program in 2010. Domestic sales were 88.4% of revenues with international sales comprising the remainder. Without the DHHS contract, our revenues would have increased 5.6%, with domestic revenues increasing 7.3% and international revenues declining 3.0%. Unit sales of the 1mL syringe increased 17.1% and 3mL unit sales increased 54.3%. Unit sales of all products increased 27.3%. Domestic unit sales as well as average sales prices increased. International unit sales decreased slightly and average selling prices increased. Cost of sales increased due to greater volumes. Royalty expenses were higher due to higher gross sales. As a result, gross profit margins increased from 29.5% in 2008 to 34.7% in 2009. Operating expenses increased from the prior year due to litigation costs and stock option expense mitigated by the cost cutting measures implemented in the third quarter of 2009. Sales and marketing expenses decreased primarily due to lower compensation attributable to staff reduction and reduction in pay, lower advertising expenses and reduced travel costs. Stock option expense and consulting costs increased. General and administrative costs increased due principally to litigation costs and stock option expense. Compensation costs decreased due to staff reductions and reductions in pay. In the fourth quarter of 2009, we recognized an impairment charge of $2,594,602 associated with catheter production equipment. "

Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that designs, manufactures, and markets innovative microsurgical instruments for ophthalmic and neurosurgical applications, announced its results for the second quarter ended January 31, 2010. The Company reported second quarter 2010 sales of $13.0 million and net income of $877,000. Second Quarter Results Second quarter 2010 sales [...]

Continue reading " Synergetics Announces Second Quarter Results "

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced results for the fourth quarter and year ended December 31, 2009. * Cubist acquired Calixa Therapeutics Inc. in December * Operating income grew 52% over 2008 * Total net revenues for 2009 increased 30% over 2008 Related posts Pet Insurance Company Hires Craig Wallace as Senior Vice President of [...]

Continue reading " Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million "

Biomet, Inc. announced financial results for its second fiscal quarter ended November 30, 2009. * Net sales increased 8% (5% constant currency) to $696 million worldwide and increased 8% in the U.S. * Reconstructive sales, excluding dental, increased 12% (9% constant currency) worldwide, with 10% U.S. growth * Knee sales increased 15% (12% constant currency) [...]

Continue reading " Biomet Announces Financial Results for Second Quarter of Fiscal Year 2010 "